Literature DB >> 28314969

[Radical prostatectomy as part of a multimodal concept for patients with prostate cancer and bone metastases at initial diagnosis].

A Spek1, A Herlemann1, C Gratzke1, C G Stief2.   

Abstract

In patients with metastatic prostate cancer presenting with synchronous bone metastases, the surgical removal of the primary is an experimental treatment approach. In the following article, we evaluate the rationale for this approach.

Entities:  

Keywords:  Hormone chemotherapy; Lymphatic metastasis; Metastasis; Multimodal approach; Therapy, cytoreductive

Mesh：

Year:  2017        PMID： 28314969     DOI： 10.1007/s00120-017-0366-8

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  18 in total

1.  Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

Authors:  Henk van der Poel; Laurence Klotz; Gerald Andriole; Abdel-Rahmène Azzouzi; Anders Bjartell; Olivier Cussenot; Freddy Hamdy; Markus Graefen; Paolo Palma; Arturo Rodriguez Rivera; Christian G Stief
Journal:  World J Urol       Date:  2015-06-03       Impact factor: 4.226

2.  A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation.

Authors:  Prasanna Sooriakumaran; Jeffrey Karnes; Christian Stief; Bethan Copsey; Francesco Montorsi; Peter Hammerer; Burkhard Beyer; Marco Moschini; Christian Gratzke; Thomas Steuber; Nazareno Suardi; Alberto Briganti; Lukas Manka; Tommy Nyberg; Susan J Dutton; Peter Wiklund; Markus Graefen
Journal:  Eur Urol       Date:  2015-05-30       Impact factor: 20.096

3.  Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry.

Authors:  Christian Gratzke; Jutta Engel; Christian G Stief
Journal:  Eur Urol       Date:  2014-05-10       Impact factor: 20.096

Review 4.  EAU guidelines on renal cell carcinoma: 2014 update.

Authors:  Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2015-01-21       Impact factor: 20.096

5.  [Active surveillance for low-risk prostate cancer].

Authors:  Annika Herlemann; Christian G Stief
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

6.  Tracking the clonal origin of lethal prostate cancer.

Authors:  Michael C Haffner; Timothy Mosbruger; David M Esopi; Helen Fedor; Christopher M Heaphy; David A Walker; Nkosi Adejola; Meltem Gürel; Jessica Hicks; Alan K Meeker; Marc K Halushka; Jonathan W Simons; William B Isaacs; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian
Journal:  J Clin Invest       Date:  2013-10-25       Impact factor: 14.808

7.  Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer.

Authors:  Jutta Engel; Patrick J Bastian; Helmut Baur; Volker Beer; Christian Chaussy; Juergen E Gschwend; Ralph Oberneder; Karl H Rothenberger; Christian G Stief; Dieter Hölzel
Journal:  Eur Urol       Date:  2010-01-20       Impact factor: 20.096

8.  The evolutionary history of lethal metastatic prostate cancer.

Authors:  Christopher Foster; Douglas Easton; Ultan McDermott; David C Wedge; G Steven Bova; Gunes Gundem; Peter Van Loo; Barbara Kremeyer; Ludmil B Alexandrov; Jose M C Tubio; Elli Papaemmanuil; Daniel S Brewer; Heini M L Kallio; Gunilla Högnäs; Matti Annala; Kati Kivinummi; Victoria Goody; Calli Latimer; Sarah O'Meara; Kevin J Dawson; William Isaacs; Michael R Emmert-Buck; Matti Nykter; Zsofia Kote-Jarai; Hayley C Whitaker; David E Neal; Colin S Cooper; Rosalind A Eeles; Tapio Visakorpi; Peter J Campbell
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

9.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

10.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

Authors:  Nicholas David James; Melissa R Spears; Noel W Clarke; David P Dearnaley; Johann S De Bono; Joanna Gale; John Hetherington; Peter J Hoskin; Robert J Jones; Robert Laing; Jason F Lester; Duncan McLaren; Christopher C Parker; Mahesh K B Parmar; Alastair W S Ritchie; J Martin Russell; Räto T Strebel; George N Thalmann; Malcolm D Mason; Matthew R Sydes
Journal:  Eur Urol       Date:  2014-10-06       Impact factor: 20.096
View more
  1 in total

Review 1.  [Cytoreductive, radical prostatectomy in metastatic prostate cancer].

Authors:  M Chaloupka; A Herlemann; A Spek; C Gratzke; C Stief
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.